<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p54" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_54{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_54{left:341px;bottom:30px;}
#t3_54{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_54{left:377px;bottom:30px;}
#t5_54{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_54{left:540px;bottom:30px;}
#t7_54{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_54{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_54{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_54{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_54{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_54{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_54{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_54{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_54{left:1098px;bottom:28px;letter-spacing:0.32px;}
#tg_54{left:36px;bottom:778px;letter-spacing:-0.23px;word-spacing:0.11px;}
#th_54{left:221px;bottom:778px;letter-spacing:-0.21px;word-spacing:-0.07px;}
#ti_54{left:728px;bottom:778px;letter-spacing:-0.28px;word-spacing:0.16px;}
#tj_54{left:1065px;bottom:575px;letter-spacing:-0.1px;}
#tk_54{left:1065px;bottom:557px;letter-spacing:-0.09px;}
#tl_54{left:1065px;bottom:539px;letter-spacing:-0.08px;}
#tm_54{left:1072px;bottom:479px;letter-spacing:-0.09px;}
#tn_54{left:1072px;bottom:460px;letter-spacing:-0.06px;}
#to_54{left:1072px;bottom:442px;letter-spacing:-0.08px;}
#tp_54{left:1072px;bottom:424px;letter-spacing:-0.09px;}
#tq_54{left:1072px;bottom:405px;letter-spacing:-0.25px;}
#tr_54{left:36px;bottom:535px;letter-spacing:-0.09px;}
#ts_54{left:36px;bottom:517px;letter-spacing:-0.09px;word-spacing:-0.15px;}
#tt_54{left:36px;bottom:498px;letter-spacing:-0.11px;}
#tu_54{left:36px;bottom:480px;letter-spacing:-0.1px;}
#tv_54{left:221px;bottom:690px;letter-spacing:-0.1px;}
#tw_54{left:221px;bottom:672px;letter-spacing:-0.1px;}
#tx_54{left:310px;bottom:679px;letter-spacing:-0.08px;}
#ty_54{left:221px;bottom:280px;letter-spacing:-0.08px;}
#tz_54{left:221px;bottom:308px;letter-spacing:-0.1px;}
#t10_54{left:221px;bottom:627px;letter-spacing:-0.1px;}
#t11_54{left:221px;bottom:565px;letter-spacing:-0.2px;}
#t12_54{left:221px;bottom:547px;letter-spacing:-0.08px;}
#t13_54{left:221px;bottom:528px;letter-spacing:-0.1px;}
#t14_54{left:221px;bottom:510px;letter-spacing:-0.09px;}
#t15_54{left:221px;bottom:492px;letter-spacing:-0.1px;}
#t16_54{left:304px;bottom:499px;}
#t17_54{left:221px;bottom:433px;letter-spacing:-0.1px;}
#t18_54{left:221px;bottom:358px;letter-spacing:-0.09px;}
#t19_54{left:221px;bottom:340px;letter-spacing:-0.11px;}
#t1a_54{left:336px;bottom:348px;letter-spacing:-0.14px;}
#t1b_54{left:439px;bottom:598px;letter-spacing:-0.1px;}
#t1c_54{left:439px;bottom:580px;letter-spacing:-0.09px;}
#t1d_54{left:439px;bottom:561px;letter-spacing:-0.09px;}
#t1e_54{left:505px;bottom:569px;}
#t1f_54{left:728px;bottom:588px;letter-spacing:-0.13px;}
#t1g_54{left:751px;bottom:595px;}
#t1h_54{left:432px;bottom:475px;letter-spacing:-0.1px;}
#t1i_54{left:432px;bottom:456px;letter-spacing:-0.09px;}
#t1j_54{left:432px;bottom:438px;letter-spacing:-0.09px;}
#t1k_54{left:498px;bottom:446px;}
#t1l_54{left:570px;bottom:551px;letter-spacing:-0.09px;}
#t1m_54{left:570px;bottom:533px;letter-spacing:-0.1px;word-spacing:-0.67px;}
#t1n_54{left:570px;bottom:514px;letter-spacing:-0.21px;word-spacing:0.13px;}
#t1o_54{left:570px;bottom:496px;letter-spacing:-0.27px;}
#t1p_54{left:566px;bottom:447px;letter-spacing:-0.08px;}
#t1q_54{left:566px;bottom:429px;letter-spacing:-0.09px;}
#t1r_54{left:726px;bottom:522px;letter-spacing:-0.1px;}
#t1s_54{left:893px;bottom:529px;letter-spacing:-0.07px;}
#t1t_54{left:912px;bottom:522px;letter-spacing:-0.09px;}
#t1u_54{left:728px;bottom:457px;letter-spacing:-0.13px;}
#t1v_54{left:752px;bottom:465px;}
#t1w_54{left:728px;bottom:439px;letter-spacing:-0.06px;}
#t1x_54{left:728px;bottom:420px;letter-spacing:-0.1px;}
#t1y_54{left:971px;bottom:428px;letter-spacing:-0.09px;}
#t1z_54{left:728px;bottom:348px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t20_54{left:916px;bottom:348px;letter-spacing:-0.11px;}
#t21_54{left:442px;bottom:362px;letter-spacing:-0.09px;}
#t22_54{left:442px;bottom:344px;letter-spacing:-0.09px;}
#t23_54{left:442px;bottom:325px;letter-spacing:-0.09px;}
#t24_54{left:442px;bottom:307px;letter-spacing:-0.11px;}
#t25_54{left:481px;bottom:315px;}
#t26_54{left:1070px;bottom:706px;letter-spacing:-0.09px;}
#t27_54{left:1070px;bottom:687px;letter-spacing:-0.08px;}
#t28_54{left:1070px;bottom:669px;letter-spacing:-0.1px;}
#t29_54{left:1070px;bottom:651px;letter-spacing:-0.25px;}
#t2a_54{left:36px;bottom:198px;}
#t2b_54{left:46px;bottom:192px;letter-spacing:0.13px;}
#t2c_54{left:247px;bottom:192px;}
#t2d_54{left:36px;bottom:182px;}
#t2e_54{left:46px;bottom:176px;letter-spacing:0.13px;}
#t2f_54{left:261px;bottom:176px;}
#t2g_54{left:36px;bottom:165px;}
#t2h_54{left:42px;bottom:159px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t2i_54{left:337px;bottom:159px;}
#t2j_54{left:36px;bottom:148px;}
#t2k_54{left:42px;bottom:142px;letter-spacing:0.12px;}
#t2l_54{left:45px;bottom:125px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2m_54{left:45px;bottom:108px;letter-spacing:0.12px;}
#t2n_54{left:174px;bottom:108px;letter-spacing:0.13px;}
#t2o_54{left:258px;bottom:108px;}
#t2p_54{left:696px;bottom:198px;}
#t2q_54{left:705px;bottom:192px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t2r_54{left:704px;bottom:176px;letter-spacing:0.03px;}
#t2s_54{left:769px;bottom:176px;}
#t2t_54{left:696px;bottom:165px;}
#t2u_54{left:702px;bottom:159px;letter-spacing:0.09px;word-spacing:0.03px;}
#t2v_54{left:704px;bottom:142px;letter-spacing:0.11px;}
#t2w_54{left:854px;bottom:142px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t2x_54{left:704px;bottom:125px;letter-spacing:0.11px;word-spacing:0.03px;}
#t2y_54{left:946px;bottom:125px;}
#t2z_54{left:696px;bottom:114px;}
#t30_54{left:709px;bottom:108px;letter-spacing:0.12px;}
#t31_54{left:741px;bottom:108px;letter-spacing:0.12px;}
#t32_54{left:819px;bottom:108px;letter-spacing:0.08px;word-spacing:0.05px;}
#t33_54{left:438px;bottom:691px;letter-spacing:-0.1px;}
#t34_54{left:438px;bottom:671px;letter-spacing:-0.09px;}
#t35_54{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_54{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_54{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_54{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_54{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_54{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_54{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_54{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_54{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s8_54{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_54{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sa_54{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sb_54{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sc_54{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts54" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg54Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg54" style="-webkit-user-select: none;"><object width="1210" height="935" data="54/54.svg" type="image/svg+xml" id="pdf54" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_54" class="t s0_54">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_54" class="t s1_54">® </span>
<span id="t3_54" class="t s0_54">(NCCN </span>
<span id="t4_54" class="t s1_54">® </span>
<span id="t5_54" class="t s0_54">), All rights reserved. NCCN Guidelines </span>
<span id="t6_54" class="t s1_54">® </span>
<span id="t7_54" class="t s0_54">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_54" class="t s2_54">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_54" class="t s2_54">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_54" class="t s3_54">NCCN Guidelines Version 4.2024 </span>
<span id="tb_54" class="t s3_54">Cancer of the Supraglottic Larynx </span>
<span id="tc_54" class="t s4_54">NCCN Guidelines Index </span>
<span id="td_54" class="t s4_54">Table of Contents </span>
<span id="te_54" class="t s4_54">Discussion </span>
<span id="tf_54" class="t s5_54">SUPRA-6 </span>
<span id="tg_54" class="t s5_54">CLINICAL STAGING </span><span id="th_54" class="t s5_54">TREATMENT OF PRIMARY AND NECK </span><span id="ti_54" class="t s5_54">ADJUVANT TREATMENT </span>
<span id="tj_54" class="t s5_54">Follow-up </span>
<span id="tk_54" class="t s6_54">(FOLL-A, 1 </span>
<span id="tl_54" class="t s6_54">of 2) </span>
<span id="tm_54" class="t s5_54">Recurrent </span>
<span id="tn_54" class="t s5_54">or </span>
<span id="to_54" class="t s5_54">persistent </span>
<span id="tp_54" class="t s5_54">disease </span>
<span id="tq_54" class="t s6_54">(ADV-3) </span>
<span id="tr_54" class="t s7_54">Requiring </span>
<span id="ts_54" class="t s5_54">(amenable to) total </span>
<span id="tt_54" class="t s5_54">laryngectomy </span>
<span id="tu_54" class="t s5_54">(most T3,N1–N3) </span>
<span id="tv_54" class="t s5_54">Concurrent systemic </span>
<span id="tw_54" class="t s5_54">therapy/RT </span>
<span id="tx_54" class="t s8_54">i,k,l </span>
<span id="ty_54" class="t s5_54">Clinical trials </span>
<span id="tz_54" class="t s5_54">or </span>
<span id="t10_54" class="t s5_54">or </span>
<span id="t11_54" class="t s5_54">Laryngectomy, </span>
<span id="t12_54" class="t s5_54">ipsilateral </span>
<span id="t13_54" class="t s5_54">thyroidectomy </span>
<span id="t14_54" class="t s5_54">with neck </span>
<span id="t15_54" class="t s5_54">dissection </span>
<span id="t16_54" class="t s8_54">h </span>
<span id="t17_54" class="t s5_54">or </span>
<span id="t18_54" class="t s5_54">Induction </span>
<span id="t19_54" class="t s5_54">chemotherapy </span>
<span id="t1a_54" class="t s8_54">k,m </span>
<span id="t1b_54" class="t s5_54">No adverse </span>
<span id="t1c_54" class="t s5_54">pathologic </span>
<span id="t1d_54" class="t s5_54">features </span>
<span id="t1e_54" class="t s8_54">j </span>
<span id="t1f_54" class="t s5_54">RT </span>
<span id="t1g_54" class="t s8_54">i </span>
<span id="t1h_54" class="t s5_54">Adverse </span>
<span id="t1i_54" class="t s5_54">pathologic </span>
<span id="t1j_54" class="t s5_54">features </span>
<span id="t1k_54" class="t s8_54">j </span>
<span id="t1l_54" class="t s5_54">Extranodal </span>
<span id="t1m_54" class="t s5_54">extension and/ </span>
<span id="t1n_54" class="t s5_54">or positive </span>
<span id="t1o_54" class="t s5_54">margin </span>
<span id="t1p_54" class="t s5_54">Other risk </span>
<span id="t1q_54" class="t s5_54">features </span>
<span id="t1r_54" class="t s5_54">Systemic therapy/RT </span>
<span id="t1s_54" class="t s8_54">i,k </span>
<span id="t1t_54" class="t s5_54">(category 1) </span>
<span id="t1u_54" class="t s5_54">RT </span>
<span id="t1v_54" class="t s8_54">i </span>
<span id="t1w_54" class="t s5_54">or </span>
<span id="t1x_54" class="t s5_54">Consider systemic therapy/RT </span>
<span id="t1y_54" class="t s8_54">i,k </span>
<span id="t1z_54" class="t s5_54">Response Assessment </span><span id="t20_54" class="t s6_54">(SUPRA-7) </span>
<span id="t21_54" class="t s5_54">CT (with contrast) or </span>
<span id="t22_54" class="t s5_54">MRI (with and without </span>
<span id="t23_54" class="t s5_54">contrast) of primary and </span>
<span id="t24_54" class="t s5_54">neck </span>
<span id="t25_54" class="t s8_54">d </span>
<span id="t26_54" class="t s5_54">Recurrent or </span>
<span id="t27_54" class="t s5_54">persistent </span>
<span id="t28_54" class="t s5_54">disease </span>
<span id="t29_54" class="t s6_54">(ADV-3) </span>
<span id="t2a_54" class="t s9_54">d </span>
<span id="t2b_54" class="t sa_54">Principles of Imaging (IMG-A)</span><span id="t2c_54" class="t sb_54">. </span>
<span id="t2d_54" class="t s9_54">h </span>
<span id="t2e_54" class="t sa_54">Principles of Surgery (SURG-A)</span><span id="t2f_54" class="t sb_54">. </span>
<span id="t2g_54" class="t s9_54">i </span>
<span id="t2h_54" class="t sa_54">Principles of Radiation Therapy (SUPRA-A)</span><span id="t2i_54" class="t sb_54">. </span>
<span id="t2j_54" class="t s9_54">j </span>
<span id="t2k_54" class="t sb_54">Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 </span>
<span id="t2l_54" class="t sb_54">or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and </span>
<span id="t2m_54" class="t sb_54">lymphatic invasion </span><span id="t2n_54" class="t sa_54">(Discussion)</span><span id="t2o_54" class="t sb_54">. </span>
<span id="t2p_54" class="t s9_54">k </span>
<span id="t2q_54" class="t sa_54">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t2r_54" class="t sa_54">(SYST-A)</span><span id="t2s_54" class="t sb_54">. </span>
<span id="t2t_54" class="t s9_54">l </span>
<span id="t2u_54" class="t sb_54">When using concurrent systemic therapy/RT, the preferred agent is </span>
<span id="t2v_54" class="t sb_54">cisplatin (category 1). </span><span id="t2w_54" class="t sa_54">See Principles of Systemic Therapy for Non- </span>
<span id="t2x_54" class="t sa_54">Nasopharyngeal Cancers (SYST-A)</span><span id="t2y_54" class="t sb_54">. </span>
<span id="t2z_54" class="t s9_54">m </span>
<span id="t30_54" class="t sb_54">See </span><span id="t31_54" class="t sa_54">Discussion </span><span id="t32_54" class="t sb_54">on induction chemotherapy. </span>
<span id="t33_54" class="t s6_54">Post Systemic Therapy/RT or RT </span>
<span id="t34_54" class="t s6_54">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t35_54" class="t sc_54">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
